Opus Genetics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Opus Genetics şirketinin toplam hissedar öz sermayesi $34.3M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $40.4M ve $6.1M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$36.64m
Eşitlik	US$34.30m
Toplam yükümlülükler	US$6.09m
Toplam varlıklar	US$40.39m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: R3X1 'nin kısa vadeli varlıkları ( $40.4M ) kısa vadeli yükümlülüklerini ( $6.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: R3X1 un uzun vadeli yükümlülüğü bulunmamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: R3X1 borçsuzdur.

Borcun Azaltılması: R3X1 şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: R3X1 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: Serbest nakit akışı her yıl % 13 oranında tarihsel oranda büyümeye devam ederse R3X1 un bir yıldan az nakit akışı süresi vardır.

Opus Genetics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Third quarter 2024 earnings released: US$0.29 loss per share (vs US$0.26 profit in 3Q 2023)

Ocuphire Pharma, Inc. (NasdaqCM:OCUP) acquired Opus Genetics, Inc. for $25.8 million.

Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75% for Pharmacologically-Induced Mydriasis in Ophthalmology

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.24 loss in 2Q 2023)

New major risk - Share price stability

Ocuphire Pharma Announces Presentations on the Development of APX3330 for Diabetic Retinopathy At Retina Meetings in June

First quarter 2024 earnings released: US$0.29 loss per share (vs US$0.28 loss in 1Q 2023)

Ocuphire Pharma, Inc., Annual General Meeting, Jun 11, 2024

Ocuphire Pharma, Inc. Announces the Enrollment of the First Subject in the LYNX-2 Phase 3 registration study

New minor risk - Profitability

Full year 2023 earnings released: US$0.46 loss per share (vs US$0.90 profit in FY 2022)

Ocuphire Pharma, Inc. Announces Appointments of Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer

Ocuphire Pharma, Inc. Announces Presentation of Clinical Data from Its ZETA-1 Trial on A Person-Level Scale Evaluating APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Investor sentiment improves as stock rises 15%

Ocuphire Pharma, Inc. Promotes Ronil Patel to Chief Business Officer, Effective as of December 1, 2023

Insufficient new directors

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Ocuphire Pharma, Inc. Announces Chief Executive Officer Changes

Investor sentiment deteriorates as stock falls 15%

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

New minor risk - Shareholder dilution

Ocuphire Pharma, Inc. to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit

Investor sentiment improves as stock rises 16%

Ocuphire Pharma, Inc. Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association's Annual Conference

Investor sentiment deteriorates as stock falls 19%

Investor sentiment deteriorates as stock falls 17%

Investor sentiment improves as stock rises 24%

Ocuphire Pharma, Inc. Announces FDA Acceptance of New Drug Application and PDUFA Date of September 28, 2023 for Nyxol Eye Drops for Reversal of Mydriasis

Ocuphire Pharma, Inc. Announces Topline Results from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy and Plans for End-of-Phase 2 Meeting with FDA

Ocuphire Pharma Announces First Patient Enrolled in Vega-2 Pivotal Phase 3 Trial of Nyxol® in Presbyopia

Ocuphire Pharma, Inc. Announces Submission of New Drug Application to FDA for Nyxol Eye Drops for Reversal of Mydriasis

Forecast to breakeven in 2022

High number of new and inexperienced directors

Forecast to breakeven in 2022

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Peer-Reviewed Publication in BMC Ophthalmology for Nyxol and Strategic Partnership with American Society of Ophthalmic Administrators

Ocuphire Expands Medical Advisory Board with Seven New Kols and Strengthens Leadership Team

Ocuphire Pharma, Inc. Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Ocuphire Pharma, Inc. to Present New Interim Masked Safety Data for Oral APX3330 in Diabetics At Annual Macula Society Meeting

Ocuphire Pharma, Inc., Annual General Meeting, Jun 13, 2022

Ocuphire Pharma, Inc. Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances

Forecast to breakeven in 2024

High number of new directors

No longer forecast to breakeven

Ocuphire Pharma, Inc. Appoints Jay Pepose as Chief Medical Advisor

Ocuphire Pharma, Inc. Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol® for Reversal of Mydriasis

Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial for Nyxol® in RM and Announces Two Upcoming Medical Conference Presentations

Ocuphire Pharma, Inc. Provides Update on its APX3330 and Nyxol Clinical Programs

Ocuphire Pharma, Inc. Initiates Enrollment of Nyxol Mira-4 Pediatric Study in Rm Per Agreed Initial Pediatric Study Plan with FDA

Forecast to breakeven in 2024

Ocuphire Pharma, Inc. Announces Enrollment of First Patients in Second Phase 3 Pivotal Trial (MIRA-3) for Nyxol® in Reversal of Mydriasis

Board Member recently bought €51k worth of stock

Insider recently bought €77k worth of stock

Ocuphire Pharma, Inc. Announces Publication in the Journal of Cellular Signaling Featuring its Oral Ref-1 Inhibitor APX3330 in Phase 2 Trial for the Treatment of Retinal Disease

Ocuphire Pharma, Inc.'s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Ocuphire Pharma, Inc. Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

Ocuphire Pharma, Inc. Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint

Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol

Ocuphire Pharma, Inc. Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology

Ocuphire Pharma, Inc. Completes Enrollment in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma, Inc. Initiates LYNX-1 Phase 3 Study Investigating Nyxol in Night Vision Disturbances

Ocuphire Pharma, Inc. Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis

Ocuphire Pharma, Inc. Appoints My Rabourn as the Vice President of Finance and Principal Accounting Officer

Ocuphire Pharma, Inc. Announces Milestones for Patents on Both of its Lead Drug Candidates Nyxol and APX3330

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin